14102 studies
The rates of increase in the incidence of type 2 diabetes mellitus (T2DM) and obesity in the world are steadily increasing and exceed even the wildest forecasts, which forces specialists to seek, develop and implement more effective therapeutic metho…
CONTEXT: Individuals with psychiatric disorders have a higher prevalence of obesity, partly because of the use of psychotropic medications. Safe and effective pharmacological interventions for weight management in this population are needed. OBJECTIV…
Acute kidney injury (AKI) remains a serious complication among individuals with type 2 diabetes. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed and often regarded as kidney-protective, yet post-marketing reports have link…
Lipedema is a chronic, progressive adipose tissue disorder that affects up to 10% of women and is characterized by disproportionate lower-limb fat accumulation, pain, edema, and resistance to conventional weight-loss approaches. Its pathophysiology i…
Cardiometabolic diseases (CVDs) are the leading cause of premature mortality and disability worldwide, arising from of cardiovascular and metabolic dysregulation. This review focuses on six critical therapeutic targets established in cardiometabolic…
Obstructive sleep apnea (OSA) is a common sleep-disordered breathing. Obesity is one of the primary risk factors for OSA, while OSA itself may promote weight gain by impairing metabolism and increasing insulin resistance, thereby creating a vicious c…
AIMS: To determine whether tirzepatide use is associated with a higher risk of osteoporosis or fragility fractures compared with other glucagon-like peptide-1 receptor agonists (GLP-1 RAs). METHODS: In a retrospective cohort study using the TriNetX n…
PURPOSE: Approximately one of ten US adults has comorbid obesity and obstructive sleep apnea (COBOSA). Traditionally, sleep medicine management of COBOSA focused on continuous positive airway pressure (CPAP). Recently, tirzepatide (a once-weekly inje…
OBJECTIVE: Limited data exist on telemedicine prescribing of semaglutide and tirzepatide. The effects of a telehealth obesity management program combining the provision of semaglutide and tirzepatide with a behavioral program tailored for long-acting…
BACKGROUND: The introduction of incretin mimetics (IMs), including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as liraglutide and semaglutide, as well as dual GLP-1/glucose-dependent insulinotropic polypeptide receptor co-agonists (GLP…
Obesity and related conditions are associated with distressing food preoccupation that often culminates in dysregulated eating behaviors. Incretin-based therapies can reduce excessive weight in obesity, but their impact on dysregulated eating behavio…
OBJECTIVE: To identify patients who may or may not benefit from use of new drugs for weight loss and to aid in minimizing loss of lean mass through proactive nutrition and exercise interventions. QUALITY OF EVIDENCE: Choices and interventions are eva…
BACKGROUND: Incretin mimetics, especially dual/triple agonists, are effective for type 2 diabetes and obesity, though mechanisms remain unclear. This study applied PET using [Ga]Ga-DO3A-Exendin-4 and [Ga]S02-GIP-T4 to assess GLP-1R and GIPR occupancy…